Cost-effectiveness of different strategies for treatmen

Journal of Forensic Toxicology & Pharmacology.ISSN: 2325-9841

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis

Aseel Bin Sawad, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio and Fatema Turkistani

Boston University, USA
Umm Al-Qura University, Saudi Arabia
University of Massachusetts Amherst Amherst, USA
University Medina, Saudi Arabia

: J Forensic Toxicol Pharmacol


Aim: To compare the cost–effectiveness of different disease-modifying therapies’ strategies for treatment of relapsing-remitting multiple sclerosis (RRMS) (Figure 1). Methods: A Markov model was developed to assess the cost–effectiveness and incremental cost–effectiveness ratios for different strategies of using disease-modifying therapies from a US third-party payer perspective. All costs were converted to 2014 US$. Results: Over 20 years, the total costs per patient were estimated at US$161,136.60 for Strategy 1 (symptom management [SM] alone), US$551,650.66 for Strategy 2 (SM and IFN-β- 1a), US$703,463.60 for Strategy 3 (SM and natalizumab) and US$670,985.24 for Strategy 4 (SM and alemtuzumab). The accumulated quality-adjusted life years were 10.49, 10.66, 10.69 and 10.71 for each of the four Strategies 1–4, respectively. The resulting incremental cost–effectiveness ratios were 2,297,141.53 comparing Strategy 2 to Strategy 1, and -1,623,918.00 comparing Strategy 4 to Strategy 3. Conclusion: Strategy 1 was the cost-effective strategy for treatment of RRMS when compared with other strategies.



Track Your Manuscript